Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the potential cost effectiveness of a 12-month fixed duration of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) in first-line chronic lymphocytic leukemia (CLL).
Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.
The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.
BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.
PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.
FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.
Panelists discuss how identifying appropriate candidates for allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute myeloid leukemia (AML) involves evaluating remission status, relapse risk based…
Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.
